Samsung Electronics has received US Patent No. 7,784,911, "Apparatus and method for printing biomolecular droplet on substrate." The patent claims a method for printing a biomolecular droplet onto a solid substrate using an electric charge concentration effect. The patent also describes an apparatus that includes a needle shaped electric field-forming electrode made of a conductive material that is disposed vertically. It includes an accommodating area and a nozzle formed on a bottom end of the accommodating area; a solid substrate that is electrically grounded and is disposed below the electric field forming electrode onto which the biomolecular droplet is discharged from the nozzle of the electric field forming electrode; and an open circuit voltage applying unit that is electrically connected to the electric-field forming electrode and applies a charge to the electric field forming electrode, causing the biomolecular droplet to be ejected onto the target surface.
Samsung has also received US Patent No. 7,785,787, "Methods of isolating and amplifying nucleic acids using silanized solid support." The patent claims methods of isolating and amplifying nucleic acids from and in a nucleic acid-containing sample. The nucleic acid isolation method includes contacting a nucleic acid-containing sample to a silanized solid support to capture nucleic acids to the silanized solid support and treating the nucleic acid-captured solid support with an alkaline solution of between pH 9 and 14. An amplification solution is then added to the resultant solution after the alkaline treatment to perform nucleic acid amplification.
Sungkyunkwan University of Suwon, Korea, has received US Patent No. 7,785,649, "Method for manufacturing protein chip substrate using plasma and protein chip substrate manufactured by the method." The patent claims a method for making a protein chip substrate. It includes deposition of plasma polymerized ethylenediamine with an amine group on plasma polymerized cyclohexane by inductively coupled plasma-chemical vapor deposition. This prevents non-specific adsorption of proteins on a slide surface, according to the patent.
Novartis Vaccines and Diagnostics of Emeryville, Calif., has received US Patent No. 7,785,782, "Device and method for in-line blood testing using biochips." The patent claims screening methods that include nucleic acid amplification techniques and antibody-antigen assays to detect target molecules and agents indicative of infectious diseases or metabolic diseases using low-density biochips. The biochips bind target agents or molecules in the blood being tested and can be used to detect the bound target agents and molecules, according to the patent. The detection of target agents or molecules is performed by a separate multiplex assay system designed to execute target and signal amplification and antibody-antigen binding reactions.
Stanford University of Palo Alto, Calif., has received US Patent No. 7,785,819, "Therapeutic and diagnostic uses of antibody specificity profiles." This patent provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and epitopes of autoantigens, allergens, and graft antigens. The antibody specificity profile is determined through the binding of patient antibodies to arrays containing antigens and epitopes.
Harvard University has received US Patent No. 7,785,790, "Replica amplification of nucleic acid arrays." The patent claims methods for producing high-density arrays of nucleic acids and replicas of such arrays, as well as methods for preserving the resolution of arrays through rounds of replication. The patent also claims methods of sequencing nucleic acids immobilized on arrays using single copies of arrays that lead to higher fidelity and longer read lengths of the sequences immobilized.
Baltic Technology Development of Tallinn, Estonia, has received US Patent No. 7,786,292, "Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease." The patent claims compounds that have a chelating moiety and an oligonucleotide sequence, where the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. According to the patent, the compounds are suitable for antisense therapy, and the chelating moiety can be complexed to an ion of a lanthanide metal. The stability of these complexes also has utility for RNAi diagnostics, antisense nucleotide therapies, and nucleic acid microarray diagnostics.
The University of Maryland of Baltimore and College Park has received US Patent No. 7,790,010, "Spatially selective deposition of polysaccharide layer onto patterned template." The patent claims a method for electrochemically depositing a polymer with spatial selectivity. According to the patent, a substrate is contacted with an aqueous solution containing a selectively insolubilizable polysaccharide, such as chitosan, which is subjected to electrochemical treatment. The selectively insolubilizable polysaccharide is then deposited on a patterned electrically conductive portion of the substrate surface.
Cyclops Genome Sciences of Cambridge, UK, has received US Patent No. 7,790,373, "Clean-up beads." The patent provides material for separating an analyte from an undesired constituent. The material includes a solid phase and a coating, where the solid phase is capable of binding the undesired constituent, and where the coating covers the exposed surface of the solid phase to an extent that any binding of the solid phase to the analyte is impeded. A method for preparing the material is also provided.
Université de Genève of Geneva, Switzerland, has received US Patent No. 7,790,379, "Mapping of proteins along chromatin by chromatin cleavage." The patent claims a method for localizing, in chromatin or DNA, the binding loci of a chromatin or DNA-binding protein. It includes: a) tethering an enzyme with regulatable activity to a chromatin binding protein on an array; b) activating the regulatable enzymatic activity bound to the targeted chromatin, and c) mapping the enzymatically modified genomic sites introduced by the enzyme into the chromatin. According to the patent, the mapping step may be carried out on specific DNA fragments, or on a chromosome-wide scale or a genome-wide scale.
SRU Biosystems of Woburn, Mass., has received US Patent No. 7,790,406, "Grating-based sensor combining label-free binding detection and fluorescence amplification and readout system for sensor." The patent describes a grating-based sensor that has a grating structure constructed and designed for both evanescent resonance fluorescence detection and label-free detection applications. One- and two-dimensional gratings are also discussed, including gratings characterized by unit cells with central posts, central holes, and two-level, two-dimensional gratings. A readout system for such sensors is also claimed.
Austrian Research Centers of Vienna and Tecnet Capital Technologiemanagement of St. Polten, Austria, have received US Patent No. 7,790,472, "Fixed support for immobilizing biomolecules." The patent claims a fixed support for immobilizing biomolecules, where the support is covered, at least partially, with a polymer. According to the patent, the polymer is an epoxy resin with functionality ranging between 4 and 15 epoxy groups per molecule. The patent also claims a method for making such a support.
Illumina of San Diego has received US Patent No. 7,791,013, "Biological microarray line scanning method and system." The patent describes a line-scanning arrangement for imaging microarrays that includes a line illuminator that converts output from one or more lasers to a radiation line. According to the patent, the laser output passes through a single mode fiber and a module that converts the laser light to the radiation line. The line is confocally directed to sites on the microarray, and retrobeams returned from the sites are collected on an imaging detector. The microarray is then moved in the imaging apparatus so as to progressively illuminate an array or matrix of sites for imaging.
Fluidigm of South San Francisco, Calif., has received US Patent No. 7,792,345, "Image processing method and system for microfluidic devices." The patent claims a method for processing an image of a microfluidic that includes receiving a first image of a microfluidic device that corresponds to a first state. Next, a second image of the microfluidic device is received that corresponds to a second state. The method also includes transforming the first image and the second image into a third coordinate space, and obtaining a third image based on information associated with the transformed first image and the transformed second image, and processing the third image to obtain information associated with the first state and the second state.